National References Laboratory for Clinical Chemistry, Ethiopian Public Health Institute, Gulelle Arbegnoch Street (the former Pasteur Institute): Gulele Sub City, Addis Ababa, Ethiopia.
Department of Biomedical Science, College of Medicine and Health Science, Wollo University, Dessie, Wollo, Ethiopia.
BMC Psychiatry. 2021 Dec 11;21(1):620. doi: 10.1186/s12888-021-03631-2.
Globally, the prevalence of metabolic syndrome (MetS) is higher among patients with schizophrenia than the general population, and this leads to higher morbidity and mortality in this population. The aim of this study was to investigate the MetS prevalence among patients with schizophrenia in Ethiopia.
We conducted a cross-sectional analysis of baseline data of 200 patients with schizophrenia recruited from Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia. Lipid profile and blood glucose levels were measured using Roche Cobas 6000 clinical chemistry analyzer. The prevalence of MetS was assessed based on National Cholesterol Education Program Adult Treatment Panel III criteria. Patients' demographic information, clinical and laboratory data, lifestyle habits, particularly smoking and Khat chewing, were evaluated vis-à-vis MetS.
The overall prevalence of MetS in patients with schizophrenia was 21.5% (17.1% male, 29.6% female) where Low HDL-cholesterol value was the most common metabolic disorders components in both males and females subgroups. In the multivariate analysis, the positive and negative symptoms score (PANSS, AOR = 1.03, 95% CI 1.001-1.054) was associated factors with MetS.
In Ethiopia, patients with schizophrenia were found to have higher prevalence of MetS than the general population. Physicians/health care providers should routinely screen patients with schizophrenia for MetS and initiate timely management of those who develop the syndrome to reduce the health cost from caring for NCDs, improve the patients' quality of life, and prevent premature mortality.
在全球范围内，与一般人群相比，精神分裂症患者的代谢综合征（MetS）患病率更高，这导致该人群的发病率和死亡率更高。本研究旨在调查埃塞俄比亚精神分裂症患者的 MetS 患病率。
我们对来自埃塞俄比亚亚的斯亚贝巴 Amanuel 精神专科医院的 200 名精神分裂症患者的基线数据进行了横断面分析。使用罗氏 Cobas 6000 临床化学分析仪测量血脂谱和血糖水平。根据国家胆固醇教育计划成人治疗小组 III 标准评估 MetS 的患病率。评估了患者的人口统计学信息、临床和实验室数据、生活方式习惯，特别是吸烟和恰特草咀嚼，与 MetS 有关。
精神分裂症患者的总体 MetS 患病率为 21.5%（男性 17.1%，女性 29.6%），其中低 HDL-胆固醇值是男性和女性亚组中最常见的代谢紊乱成分。在多变量分析中，阳性和阴性症状评分（PANSS，AOR=1.03，95%CI 1.001-1.054）是与 MetS 相关的因素。
在埃塞俄比亚，精神分裂症患者的 MetS 患病率高于一般人群。医生/医疗保健提供者应常规筛查精神分裂症患者的 MetS，并及时对出现该综合征的患者进行管理，以降低治疗非传染性疾病的医疗费用，提高患者的生活质量，预防过早死亡。
